Table 2: Therapeutic effects of Graptopetalum paraguayense (GP) on DMN-induced liver fibrosis in rats via biochemical analysis (1).

Categorical variable

Numeric variableDMNDMN + GP
Control (n)a1st to 2nd wk (n)b3rd to 4th wk (n)b5th to 6th wk (n)b2nd wk (n)c3rd to 4th wk (n)c5th to 6th wk (n)c

Albumin (g/dL)4.6 ± 0.3 (23)3.9 ± 0.7 (07)3.5 ± 0.6 (11)3.2 ± 0.1 (07)3.7 ± 0.5 (06)4.0 ± 0.7 (12)4.3 ± 0.6 (14)
GPT (U/L)58.8 ± 19.6 (23)459.5 ± 78.5 (08)566.6 ± 313.5 (11)763.6 ± 405.2 (07)235.0 ± 128.6 (06)207.0 ± 111.7 (12)262.5 ± 386.2 (14)
GOT (U/L)101.9 ± 30.4 (23)661.5 ± 134.4 (08)1006.1 ± 749.6 (11)1572.9 ± 965.3 (07)271.3 ± 106.0 (06)190.4 ± 114.5 (12)218.0 ± 259.6 (14)
Bilirubin (mg/dL)0.11 ± 0.04 (24)0.72 ± 0.53 (08)1.00 ± 0.74 (11)1.13 ± 1.00 (07)0.25 ± 0.14 (06)0.25 ± 0.20 (12)0.3 ± 0.32 (14)
AKP (KA)45.9 ± 7.5 (12)600.8 ± 93.0 (04)668.3 ± 222.0 (03)468 ± 12.7 (02)298.2 ± 65.8 (04)353.3 ± 62.3 (08)374.0 ± 88.3 (11)
LDH (IU/L)280.5 ± 49.0 (11)414.8 ± 102.7 (04)562.0 ± 120.8 (03)853.5 ± 91.2 (02)352.0 ± 21.9 (04)378.6 ± 36.1 (08)329.5 ± 67.6 (11)
Globulin (g/dL)7.0 ± 0.4 (11)6.65 ± 0.1 (02)5.0 ± 0.84 (04)3.6 ± 03 (02)5.9 ± 0.6 (04)5.7 ± 0.5 (08)5.9 ± 1.0 (11)
Triglyceride (mg/dL)148.0 ± 33.7 (12)151.3 ± 107.3 (04)180.9 ± 144.4 (07)102.8 ± 35.1 (05)73.0 ± 26.9 (02)96.5 ± 29.9 (08)98.3 ± 32.2 (11)
AFP (ng/dL)0.26 ± 0.06 (10)0.40 ± 0.19 (04)0.38 ± 0.05 (04)0.35 ± 0.07 (02)0.20 ± 0.00 (02)0.28 ± 0.13 (08)0.26 ± 0.08 (10)
CHOL (mg/dL)83.2 ± 0.14.1 (12)76.5 ± 7.9 (04)69.5 ± 12.8 (06)66.6 ± 17.5 (05)60.0 ± 5.0 (04)65.9 ± 15.5 (08)70.8 ± 18.6 (11)
BUN (mg/dL)27.2 ± 6.0 (12)32.5 ± 3.9 (04)36.25 ± 2.2 (04)30.5 ± 4.9 (02)18.8 ± 3.9 (04)20.9 ± 2.2 (08)30.6 ± 23.0 (11)
ACP (mg/dL)2.4 ± 0.6 (12)1.9 ± 0.6 (04)6.2 ± 1.1 (04)8.2 ± 0.6 (02)3.8 ± 0.6 (04)5.0 ± 1.5 (08)3.7 ± 1.1 (11)
PT (sec)13.1 ± 1.1 (22)18.5 ± 4.0 (08)19.7 ± 4.3 (09)21.5 ± 4.6 (06)16.1 ± 2.6 (06)17.2 ± 5.4 (10)16.3 ± 2.9 (13)
PLT (103/mL)871.5 ± 191.8 (24)406.6 ± 71.7 (07)300.2 ± 164.7 (11)228.6 ± 302.4 (07)535.3 ± 137.9 (06)548.9 ± 259.1 (12)704.5 ± 301.1 (14)

a: Mean ± SD of value from 1st to 6th week in control groups.
b: Mean ± SD of value from 1st to 2nd, 3rd to 4th or 5th to 6th week in DMN treatment groups.
c: Mean ± SD of value from 2nd, 3rd to 4th or 5th to 6th week in DMN+GP treatment groups.
n: number of rats.